Teijin Pharma Limited

National Institute of Infectious Diseases

Teijin Limited

Tokyo Institute of Technology

Denka Company Limited

The Kitasato Institute

Sumitomo Pharma Co., Ltd.

Abal Inc.

Yoshimasa Takahashi

Asahi Kawana

Chikashi Kanazawa

Takashi Shirakura

Susumu Takeuchi

Yu Adachi

Yasunori Nakayama

Yoshiaki Azuma

Eiji Ochiai

Akinobu Maruyama

Kei Yamana

Hitoshi Wada

Manabu Ato

Kazuhiko Katayama

Motohiro Miki

Tsuyoshi Nomura

Yoshikatsu Kanemaru

Akira Tanokura

Shota Suzuki

Akihisa Fukushima

Hiroshi Saitoh

Reiko Todaka

Takafumi Ueno

Yoshiya Okoyama

Masayuki Tera

Mariko Imazeki

Hiroyuki Takahashi

Mizuho Tamura

Ippei Kuwahara

Kengo Yoshikawa

Megumi Mano

Hirofumi Kamada

Taishi Onodera

Mika Fujinuma

Ueno Takafumi

Yoshikawa Kengo

Mano Megumi

The present invention provides a composition comprising a universal influenza vaccine antigen and a vaccine adjuvant.

Composition containing influenza vaccine

A virtual space experience system capable of preventing unintentional contact between players without inhibiting a sense of immersion is provided. A virtual space image determination unitof a VR system S causes an image of a virtual space to be perceived by a second player to include an image in which a first avatar corresponding to a first player moves so as to generate a gap in a correspondence relationship between coordinates of the first player and coordinates of the first avatar when a trigger event is recognized, and causes the image of the virtual space to be perceived by the second player to include an image of a second avatar corresponding to the second player and a third avatar corresponding to the first player after the recognition. An avatar coordinate determination unitdetermines coordinates of the third avatar based on the coordinates of the first player.

Virtual space experience system

Provided is a method for producing an influenza HA split vaccine which produces an antibody that binds to a HA stem region of influenza, the HA stem region being less likely to cause antigenic variation, An influenza HA split vaccine is subjected to an acidic treatment. Through the acidic treatment, an influenza HA split vaccine which produces an antibody that binds to a LAH of the HA stem region is obtained. This influenza HA split vaccine has an excellent protective ability against infection of other influenza viruses of different antigenicity.

Method for producing influenza HA split vaccine

The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L-X&#x2014;Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; Lrepresents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].

Composite polypeptide monomer, aggregate of said composite polypeptide monomer having cell penetration function, and norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration and having said aggregate as effective component thereof

Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.

Xanthine oxidase inhibitor

Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.

Pyrazine derivatives

Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome. 

Pyridine derivative

Provided are a compound expressed by formula (I) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [In the formula, A, X, Y, Z, R, and Rhave the meaning set forth in claim]. 

Pyrazole derivative

The present invention relates to a therapeutic drug or a preventive drug for hypertension or high-normal blood pressure, comprising (a) and (b) as active ingredients:  The present invention also relates to a therapeutic method or a preventive method for hypertension or high-normal blood pressure, comprising administering the above (a) and (b) in amounts effective for treating or preventing hypertension or high-normal blood pressure.

Therapeutic drug for hypertension or prehypertension

The present invention provides: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient. 

Azole benzene derivative

[PROBLEMS] To provide a polypeptide having a novel structure and showing an activity of inhibiting angiogenesis or an activity of inhibiting osteoclastogenesis, and to provide a recombinant protein by constructing a method of purifying the above protein. To provide an ingredient useful in designing remedies for tendinitis, rheumatoid arthritis, arthritis deformans, malignant tumor, etc. [MEANS FOR SOLVING PROBLEMS] A novel soluble polypeptide protein.

Protein and production process and use thereof

[Problems] To provide a polypeptide having a novel structure and showing an activity of inhibiting angiogenesis or an activity of inhibiting osteoclastogenesis, and to provide a recombinant protein by constructing a method of purifying the above protein. To provide an ingredient useful in designing remedies for tendinitis, rheumatoid arthritis, arthritis deformans, malignant tumor, etc. [Means for Solving Problems] A novel soluble polypeptide protein.

Growing community of inventors

Tokyo, Japan

Yoshimasa Takahashi